Abstract: Oligosaccharide mixtures consisting of at least one N-acetyl-lactosamine, at least one sialylated oligosaccharide, and at least one fucosylated oligosaccharide are provided. Food products, especially infant formula, comprising the oligosaccharide mixture are also provided.

Abstract: Oligosaccharide mixtures consisting of at least one N-acetyl-lactosamine, at least one sialylated oligosaccharide, and at least one fucosylated oligosaccharide are provided. Food products, especially infant formula, comprising the oligosaccharide mixture are also provided.

Abstract: The invention discloses an oligosaccharide mixture comprising at least one N-acetyl-lactosamine, at least one sialylated oligosaccharide, and at least one fucosylated oligosaccharide. Food product, especially infant formula, comprising said oligosaccharide mixture.

Abstract: The invention discloses an oligosaccharide mixture comprising 5-70 wt % of at least one N-acetylated oligosaccharide, 5-90 wt % of at least one neutral oligosaccharide, 2-50 wt % of at least one sialylated oligosaccharide, and/or 5-70 wt % of at least one fucosylated oligosaccharide. The invention also discloses a food product, especially an infant formula, comprising said oligosaccharide mixture.

Abstract: The invention discloses an oligosaccharide mixture comprising 5-70 wt % of at least one N-acetylated oligosaccharide, 5-90 wt % of at least one neutral oligosaccharide, 2-50 wt % of at least one sialylated oligosaccharide, and/or 5-70 wt % of at least one fucosylated oligosaccharide. The invention also discloses a food product, especially an infant formula, comprising said oligosaccharide mixture.

Abstract: A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.

Abstract: The invention discloses an oligosaccharide mixture comprising at least one N-acetyl-lactosamine, at least one sialylated oligosaccharide, and at least one fucosylated oligosaccharide. Food product, especially infant formula, comprising said oligosaccharide mixture.

Abstract: The invention discloses an oligosaccharide mixture comprising 5-70 wt % of at least one N-acetylated oligosaccharide, 5-90 wt % of at least one neutral oligosaccharide, 2-50 wt % of at least one sialylated oligosaccharide, and/or 5-70 wt % of at least one fucosylated oligosaccharide. The invention also discloses a food product, especially an infant formula, comprising said oligosaccharide mixture.

Abstract: A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.

Abstract: The present invention pertains to novel microorganisms of the genus Bifidobacterium, that are useful in preventing diarrhea brought about by pathogenic bacteria. In particular, the present invention relates to the use of said microorganisms for the preparation of an ingestable support and to a composition containing the same.

Abstract: A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.

Abstract: A lactic bacteria strain that is exogenous to the oral microflora is selected for its ability to adhere the pellicle of the teeth and to produce a growth inhibition factor. This strain is used for the preparation of a composition intended for reducing dental plaque and for treating or preventing root caries and other diseases related to Actinomyces naeslundii in mammals.

Abstract: The present invention pertains to novel microorganisms of the genus Bifidobacterium, that are useful in preventing diarrhea brought about by pathogenic bacteria. In particular, the present invention relates to the use of said microorganisms for the preparation of an ingestable support and to a composition containing the same.

Abstract: Compositions for the prophylaxis or treatment of dental caries, dental plaque, and periodontal infection that include lactic bacteria that are not part of the resident microflora of the mouth, that are low acidifying, and that are capable of adhering directly to the pellicle of the teeth. The compositions are used in methods of treating or preventing dental caries, dental plaque, and periodontal infection.

Abstract: The present invention provides compositions for the prophylaxis or treatment of dental caries, dental plaque, and periodontal infection that include lactic bacteria that are not part of the resident micriflora of the mouth, that are low acidifying, and that are capable of adhering directly to the pellicle of the teeth. Preferably, the lactic bacteria of the include one or more of Streptococcus thermophilus, Lactococcus lactis subsp. lactis, or Lactococcus lactis subsp. lactis biovar diacetylactis. The compositions are used in methods of treating or preventing dental caries, dental plaque, and periodontal infection.

Abstract: A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.

Abstract: Compositions for the prophylaxis or treatment of dental caries, dental plaque, and periodontal infection that include lactic bacteria that are not part of the resident microflora of the mouth, that are low acidifying, and that are capable of adhering directly to the pellicle of the teeth. The compositions are used in methods of treating or preventing dental caries, dental plaque, and periodontal infection.

Abstract: The present invention relates to an isolated and purified strain of the species Lactobacillus sanfranciscensis which produces levan. The present invention further relates to a method of producing the levan, and to a method of preparing various human or pet food products or cosmetic products which utilizes the levan and/or a strain producing the same.

Abstract: The present invention pertains to novel microorganisms of the genus Bifidobacterium, that are useful in preventing diarrhea brought about by pathogenic bacteria. In particular, the present invention relates to the use of said microorganisms for the preparation of an ingestable support and to a composition containing the same.

Abstract: Novel microorganisms of the family Lactobacillaceae and pharmaceutical compositions, food and methods of using same are provided. The microorganisms have the ability of preventing colonization of the intestine with pathogenic bacteria causing diarrhea and of preventing infection of intestinal epithelial cells by rotaviruses. The microorganisms can be used for the preparation of an ingestable support and to compositions containing same.